Prasad Megha, Ahmad Yousif, Howard James P, Ben-Ami Johanna, Madhavan Mahesh V, Kirtane Ajay J, McEntegart Margaret, Flattery Erin, Stone Gregg W, Leon Martin B, Moses Jeffrey W
NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York.
Yale School of Medicine, Yale University, New Haven, Connecticut.
J Soc Cardiovasc Angiogr Interv. 2023 May 19;2(4):100636. doi: 10.1016/j.jscai.2023.100636. eCollection 2023 Jul-Aug.
To compare the long-term incidence of myocardial infarction (MI) and death in patients randomized to coronary artery bypass grafting (CABG) vs percutaneous coronary intervention (PCI) for treatment of isolated left anterior descending (LAD) coronary artery disease.
We systematically identified all randomized controlled trials comparing PCI with stenting to CABG with a left internal mammary artery (LIMA) graft in patients with isolated LAD disease who had at least 4 years of follow-up. The primary outcome of interest was MI. Secondary outcomes were all-cause mortality and target vessel revascularization (TVR).
Four trials were included in the current analysis, with a total of 573 patients randomized to CABG with a LIMA (n = 285) vs PCI (n = 288) and followed for 4 to 10 years. At latest follow-up (weighted mean 8.3 years), there was no statistically significant difference in the risk of MI between CABG and PCI (relative risk [RR], 1.33; 95% CI, 0.62-2.83; = .46), nor was there a statistically significant difference in mortality between the groups (RR, 1.04; 95% CI, 0.70-1.65; = .84). There was a significantly lower risk of TVR after CABG compared with PCI (RR, 0.27; 95% CI, 0.15-0.46; < .001).
The current meta-analysis suggests that there is insufficient evidence that CABG with a LIMA confers protection against MI or death compared to PCI with a stent for isolated LAD disease. CABG was, however, associated with reduced rates of TVR.
比较接受冠状动脉旁路移植术(CABG)与经皮冠状动脉介入治疗(PCI)的孤立性左前降支(LAD)冠状动脉疾病患者心肌梗死(MI)和死亡的长期发生率。
我们系统地识别了所有比较PCI与支架置入术和CABG与左乳内动脉(LIMA)移植术治疗孤立性LAD疾病且至少随访4年的随机对照试验。感兴趣的主要结局是MI。次要结局是全因死亡率和靶血管血运重建(TVR)。
本分析纳入了4项试验,共有573例患者被随机分配接受LIMA的CABG(n = 285)与PCI(n = 288),并随访4至10年。在最新随访时(加权平均8.3年),CABG和PCI之间MI风险无统计学显著差异(相对风险[RR],1.33;95%CI,0.62 - 2.83;P = 0.46),两组之间死亡率也无统计学显著差异(RR,1.04;95%CI,0.70 - 1.65;P = 0.84)。与PCI相比,CABG后TVR风险显著更低(RR,0.27;95%CI,0.15 - 0.46;P < 0.001)。
当前荟萃分析表明,与PCI相比,没有足够证据表明LIMA的CABG对孤立性LAD疾病具有预防MI或死亡的作用。然而,CABG与TVR发生率降低相关。